• Home
  • Overview
    • Results of the early benefit assessment
      • G-BA procedures
      • Resolutions
      • Subgroups
      • Patients
    • Indication areas (G-BA)
      • Eye diseases
      • Skin diseases
      • Cardiovascular diseases
      • Infectious diseases
      • Respiratory system diseases
      • Hematopoietic diseases
      • Musculoskeletal system diseaeses
      • Nervous system diseases
      • Genitourinary system diseases
      • Digestive system diseases
      • Oncological diseases
      • Mental illnesses
      • Other diseases
      • Metabolic diseases
      • Orphan Drugs
    • Special marketing authorisations
      • Orphan drugs
      • PUMA
      • Evidence transfer
      • ATMP
      • ATMP CAR-T cells
      • Reserve antibiotics
      • Conditional marketing authorisation
      • Approval under exceptional circumstances
      • Accelerated assessment
      • Procedures without a dossier
    • Results of reassessments
      • Limitation
      • G-BA request (§13 VerfO)
      • Manufacturer's request (§14 VerfO)
      • Orphan drugs, turnover exceeding €50m
      • Orphan drugs, loss of status
    • G-BA requirements
      • Collection of routine practice data (AbD)
      • Quality requirements for ATMP
      • Bundling
      • Repealed resolutions
  • Procedures
    • G-BA resolutions
    • G-BA active procedures
    • EMA CHMP positive opinions
    • Arbitrations
  • Reimbursement prices
    • Recent price changes
    • Arbitration results
    • Discontinuations
    • Special practice conditions
    • Exclusions from prescription
    • Changes in legal regulations
  • Interactive Analysis
    • Resolutions
    • Subgroups
  • Intelligent search
  • Fundamentals
    • AMNOG Monitor step by step
      • Detailed analysis for each G-BA resolution
      • Interactive analysis
      • Interactive analysis: Excel export
      • Interactive analysis: Bookmarks
      • Interactive analysis: dimensions
      • Intelligent search
      • Monthly report
      • AMNOG Monitor app
      • Calculation methods
    • Changes in legal regulations
    • Arbitration board
    • EMA regulatory procedure
    • EU HTA
    • Technical terms English-German
  • Contact
    • Contact form
    • Legal notice
    • Privacy policy
Logo AMNOG-Monitor.com
Search G-BA resolutions

Login:

Login
  • Deutsch
  • English
  • Limitation
  • G-BA request (§13 VerfO)
  • Manufacturer's request (§14 VerfO)
  • Orphan drugs, turnover exceeding €50m
  • Orphan drugs, loss of status

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.
Login

 

www.AMNOG-monitor.com > Overview > Results of reassessments > Orphan drugs, turnover exceeding €50m

AMNOG monitor · Institut für Pharmakologie und präventive Medizin (IPPMED) Dr. Bramlage & Dr. Hankowitz Partnerschaft · www.ippmed.de